PGS

PGD

Tests for Ovarian & Breast Cancer

NACE

N – Non Invasive, A – Analysis, C – Chromosomal, E - Examination

The NACE test is a non-invasive prenatal test. It detects abnormalities such as down’s syndrome using a simple blood test. It is completely safe for the patient and the baby. It is a small sample of blood drawn from your arm just like for any other routine blood test. This test can be done from the 10-13th week of pregnancy.
The NACE test uses advanced technology to compare foetal DNA with the mother’s DNA to detect certain abnormalities with great precision and reliability. During pregnancy, a baby’s DNA mixes with its mother’s blood DNA. Progress in the field of genetics makes it possible for us to detect this DNA in the mother’s blood and screen genetic data regarding the baby’s chromosomes.
The NACE test screens for chromosomal abnormalities in the baby. Human beings have 23 pairs of chromosomes with a total of 46 (two copies of each pair). The first 22 pairs are numbered from 1 to 22 which are autosomes. The last pair determines our sex. Girls have two X chromosomes and boys have one X chromosome and one Y chromosome. Health and development issues appear if there is a missing or extra chromosome. When there is an additional copy of a chromosome (i.e. three copies instead of two), it is called a trisomy.
NACE detects with maximum accuracy foetuses with Down’s syndrome. Likewise, it detects other frequent chromosomal alterations (chromosomes 18, 13, X and Y) with an equally high reliability rate.
The test can be performed from the 10th week of your pregnancy.

Indications:

  • Chromosomal abnormalities
  • Pregnant patients with more than 35 years of age
  • Patients conceived by IVF treatment both by own or Donor programme

The NACE test gives more information about the risk of the most frequent foetal aneuploidies than triple screening during the 1st trimester, decreasing the rate of false positives and negatives.

ERA (ENDOMETRIAL RECEPTIVITY ARRAY)

ERA determines whether or not the patient will be responsive to embryo implantation based on the status of the endometrium. ERA identifies the day (window of implantation) when the embryo is capable of implanting in the uterus. It’s done for patients with recurrent implantation failure.

ERA examines the expression of 238 genes from a biopsy taken from the endometrium and the biopsy is taken

In a Natural LH surge on day 7
During HCG injection on day 7 and
For HRT patients on 5th day from the start of progesterone.
Source: IVIOMICS

IVIOMICS INDIA

13, Olaf Palme Marg
110057 VasantVihar
New Delhi, India
Ph : +91 11 6651 7800
Email :info.india@iviomics.com, www.iviomics.com

ADVANTAGES

Our team enables testing of PGS and PGD simultaneously which results in reports being generated within 24 hours of receipt of sample in most cases. This unique approach enables transfer of embryo without the need to freeze the embryos, spend months waiting for results or make unnecessary repeated trips to the IVF centre.

We are in collaboration with two renowned labs who perform array CGH & NGS techniques. For further details please contact:

gg lab partner
gg partner